Table 1.
Patient characteristics
| |
|
Diabetes status at cancer diagnosis |
|
||||
|---|---|---|---|---|---|---|---|
| |
Overall (N = 2,418) |
Previously diagnosed (n = 1,784) |
Previously undiagnosed (n = 634) |
P-value |
|||
| N | % (SD) | n | % (SD) | n | % (SD) | ||
|
Age at cancer diagnosis (years) | |||||||
|
66-70 |
326 |
13.5% |
234 |
13.1% |
92 |
14.5% |
0.77 |
|
71-75 |
529 |
21.9% |
397 |
22.3% |
132 |
20.8% |
|
|
76-80 |
594 |
24.6% |
437 |
24.5% |
157 |
24.8% |
|
|
>80 |
969 |
40.1% |
716 |
40.1% |
253 |
39.9% |
|
|
Mean & (SD) age |
77.8 |
6.9 |
77.8 |
7.0 |
77.7 |
6.9 |
|
|
Race/ethnicity | |||||||
|
White |
2,156 |
89.2% |
1,584 |
88.8% |
572 |
90.2% |
0.47 |
|
Black |
132 |
5.5% |
103 |
5.8% |
29 |
4.6% |
|
|
Hispanic |
89 |
3.7% |
64 |
3.6% |
25 |
3.9% |
|
|
Other |
41 |
1.7% |
33 |
1.8% |
8 |
1.3% |
|
|
Year of diagnosis | |||||||
|
2001 |
464 |
19.2% |
322 |
18.0% |
142 |
22.4% |
0.05 |
|
2002 |
482 |
19.9% |
347 |
19.5% |
135 |
21.3% |
|
|
2003 |
466 |
19.3% |
347 |
19.5% |
119 |
18.8% |
|
|
2004 |
468 |
19.4% |
363 |
20.3% |
105 |
16.6% |
|
|
2005 |
538 |
22.2% |
405 |
22.7% |
133 |
21.0% |
|
|
Stage at diagnosis | |||||||
|
In situ |
274 |
11.3% |
217 |
12.2% |
57 |
9.0% |
<0.0001 |
|
I |
920 |
38.0% |
705 |
39.5% |
215 |
33.9% |
|
|
II |
786 |
32.5% |
579 |
32.5% |
207 |
32.6% |
|
|
III |
239 |
9.9% |
175 |
9.8% |
64 |
10.1% |
|
|
IV |
199 |
8.2% |
108 |
6.1% |
91 |
14.4% |
|
|
Estrogen (ER) and progesterone (PR) receptor status | |||||||
|
ER and PR positive |
1,193 |
49.3% |
881 |
49.4% |
312 |
49.2% |
|
|
ER or PR positive |
327 |
13.5% |
238 |
13.3% |
89 |
14.0% |
0.89 |
|
ER and PR negative |
324 |
13.4% |
244 |
13.7% |
80 |
12.6% |
|
|
Unknown/missing |
574 |
23.7% |
421 |
23.6% |
153 |
24.1% |
|
|
Histologic grade | |||||||
|
1 |
447 |
18.5% |
336 |
18.8% |
111 |
17.5% |
0.61 |
|
2 |
872 |
36.1% |
652 |
36.5% |
220 |
34.7% |
|
|
3 |
696 |
28.8% |
502 |
28.1% |
194 |
30.6% |
|
|
4 |
71 |
2.9% |
49 |
2.7% |
22 |
3.5% |
|
|
Unknown/missing |
332 |
13.7% |
245 |
13.7% |
87 |
13.7% |
|
|
NCI Comorbidity Index | |||||||
|
0 |
1,051 |
43.5% |
627 |
35.1% |
410 |
64.7% |
<0.0001 |
|
1 |
699 |
28.9% |
560 |
31.4% |
145 |
22.9% |
|
|
≥ 2 |
668 |
27.6% |
597 |
33.5% |
79 |
12.5% |
|
|
Indicators of poor performance | |||||||
|
0 |
1,169 |
48.3% |
692 |
38.8% |
477 |
75.2% |
<0.0001 |
|
≥ 1 |
1,249 |
51.7% |
1,092 |
61.2% |
157 |
24.8% |
|
|
Types of physician visits | |||||||
|
Primary care and medical specialist |
1,621 |
67.0% |
1,277 |
71.6% |
344 |
54.3% |
<0.0001 |
|
Primary care, no medical specialist |
381 |
15.8% |
254 |
14.2% |
127 |
20.0% |
|
|
Medical specialist, no primary care |
226 |
9.3% |
154 |
8.6% |
72 |
11.4% |
|
|
Other specialist only |
57 |
2.4% |
34 |
1.9% |
23 |
3.6% |
|
|
None |
133 |
5.5% |
65 |
3.6% |
68 |
10.7% |
|
|
Preventive services | |||||||
|
0 |
236 |
9.8% |
123 |
6.9% |
113 |
17.8% |
<0.0001 |
|
1 |
403 |
16.7% |
294 |
16.5% |
109 |
17.2% |
|
|
≥ 2 |
1,779 |
73.6% |
1,367 |
76.6% |
412 |
65.0% |
|
|
Percent in census tract with some college | |||||||
|
<25% |
883 |
36.5% |
656 |
36.8% |
227 |
35.8% |
0.66 |
|
≥25% |
1,535 |
63.5% |
1,128 |
63.2% |
407 |
64.2% |
|
|
Percent in census tract living in poverty | |||||||
|
<5% |
686 |
28.4% |
509 |
28.5% |
177 |
27.9% |
0.29 |
|
5-7% |
343 |
14.2% |
255 |
14.3% |
88 |
13.9% |
|
|
8-12% |
542 |
22.4% |
383 |
21.5% |
159 |
25.1% |
|
|
>12% |
847 |
35.0% |
637 |
35.7% |
210 |
33.1% |
|
|
Type of geographic area | |||||||
|
Large metropolitan |
1,298 |
53.7% |
952 |
53.4% |
346 |
54.6% |
0.74 |
|
Metropolitan |
696 |
28.8% |
510 |
28.6% |
186 |
29.3% |
|
|
Urban |
165 |
6.8% |
125 |
7.0% |
40 |
6.3% |
|
| Less urban/rural | 259 | 10.7% | 197 | 11.0% | 62 | 9.8% | |
SD: Standard deviation. The NCI Comorbidity Index is based on claims 24 – 4 months before cancer, and excludes two diabetes-related conditions.